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Auckland, New ZealandBackground & Aims: Long-term treatment with tenofovir diso- tolerated, and renal events were mild and infrequent (8.6%).
proxil fumarate (TDF) alone, or in combination with emtric- The mean change in bone mineral density at week 240 was
itabine (FTC) is associated with sustained viral suppression in
patients with lamivudine resistant (LAM-R) chronic hepatitis B
(CHB).
Methods: LAM-R CHB patients were randomised 1:1 to receive
TDF 300 mg or FTC 200 mg and TDF 300 mg once daily in a
prospective, double blind, study. The proportion of patients with
plasma hepatitis B virus (HBV) DNA <69 IU/ml (<400 copies/ml)
at week 96 (primary efficacy endpoint) was reported previously.
Here we present week 240 follow-up data.
Results: Overall, 280 patients were randomised to receive TDF
(n = 141) or FTC/TDF (n = 139), and 85.4% completed 240 weeks
of treatment. At week 240, 83.0% of patients in the TDF arm,
and 82.7% of patients in the FTC/TDF treatment arm had HBV
DNA <69 IU/ml (p = 0.96). Rates of normal alanine aminotrans-
ferase (ALT) and normalised ALT were similar between groups
(p = 0.41 and p = 0.97 respectively). Hepatitis B e antigen loss
and seroconversion at week 240 were similar between groups,
(p = 0.41 and p = 0.67 respectively). Overall, six patients achieved
hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF
arm) had HBsAg seroconversion by week 240. No TDF resistance
was observed up to week 240. Treatment was generally wellJournal of Hepatology 20
Keywords: Tenofovir disoproxil fumarate; Emtricitabine; Lamivudine resistant;
Viral suppression; Bone mineral density; Renal function.
Received 1 April 2016; received in revised form 5 August 2016; accepted 9 August
2016; available online 18 August 2016
⇑ Corresponding author. Address: Toronto General Hospital, University Health
Network, 200 Elizabeth Street, 9EN-230, Toronto, Ontario M5G 2C4, Canada. Tel.:
+1 416 340 3893; fax: +1 416 340 3258.
E-mail address: scott.fung@uhn.ca (S. Fung).0.98% and 2.54% at the spine and hip, respectively.
Conclusions: TDF monotherapy was effective and well tolerated
in LAM-R CHB patients for up to 240 weeks.
Lay summary: The goal of oral antiviral treatment for chronic
hepatitis B (CHB) is to achieve and maintain undetectable HBV
DNA levels. Treatment options with enhanced potency, and low
risk of resistance development for patients infected with lamivu-
dine resistant (LAM-R) HBV are required. Tenofovir disoproxil
fumarate (TDF) monotherapy was effective and well tolerated
without TDF resistance development in CHB patients with
LAM-R, for up to 240 weeks.
Clinical trial number: NCT00737568.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The goal of oral antiviral treatment for chronic hepatitis B (CHB)
is to achieve and maintain undetectable hepatitis B virus (HBV)
DNA levels, thus slowing or preventing disease progression to cir-
rhosis and hepatocellular carcinoma (HCC) [1–3]. The first
approval of lamivudine (LAM) in 1996 (by the European Medici-
nes Agency) [4] was a major breakthrough in CHB management;
however, the subsequent rising rate of resistance development
has limited the long-term effectiveness of this agent [5]. Lok
and colleagues found that 65% of hepatitis B e antigen (HBeAg)-
positive patients developed LAM-resistant (LAM-R) mutations
after 5 years of treatment [5]. Despite this important limitation,
LAM remains a widely prescribed antiviral agent for CHB,17 vol. 66 j 11–18
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particularly in under-resourced countries due to its availability
and low cost [6]. Therefore, there continues to be a need for
newer treatments for LAM-R CHB [7].
Previous strategies to treat LAM resistance have included
switching to adefovir dipivoxil (ADV) monotherapy or adding
ADV to LAM or, more recently, switching to entecavir (ETV), but
these have not proven to be highly effective [8–10]. Tenney and
colleagues found that the cumulative probability of genotypic
ETV resistance and resistance associated with breakthrough
was 51% and 43%, respectively, in LAM-refractory patients who
were switched to ETV monotherapy for up to 5 years [9]. Further-
more, Lee and colleagues demonstrated insufficient antiviral effi-
cacy in LAM-R and entecavir-resistant (ETV-R) patients treated
with combination therapy [8]. At 2 years, approximately 50% of
patients treated with ADV in combination with a nucleoside
analogue achieved complete virological suppression (44.3% with
telbivudine plus ADV and 51.4% with ETV plus ADV) [8]. This
highlights the need for therapeutic alternatives with enhanced
potency for patients infected with LAM-R HBV.
We previously reported that tenofovir disoproxil fumarate
(TDF) either alone or in combination with emtricitabine (FTC)
has the potential to suppress HBV DNA levels in LAM-R CHB
patients without resistance development up to week 96 [11,12].
Here we present the long-term efficacy and safety results, after
5 years of treatment with TDF or FTC/TDF in LAM-R patients.Screened
N = 752
Randomised
N = 280
Randomised and treated
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TDF
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Discontinued
treatment prior
to week 240
n = 20*
Discontinued
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Fig. 1. CONSORT flow diagram. FTC, emtricitabine; TDF, tenofovir disoproxil
fumarate. *Investigator’s discretion (n = 6), withdrew consent (n = 5), safety/tol-
erability/efficacy reasons (n = 3), lost to follow-up (n = 3), protocol violation
(n = 2), study discontinued at site (n = 1). yInvestigator’s discretion (n = 5),
withdrew consent (n = 6), safety/tolerability/efficacy reasons (n = 4), lost to
follow-up (n = 3), protocol violation (n = 3).Materials and methods
Patients
This was a prospective, randomised, double blind, double-dummy, multi-centre
240-week study (ClinicalTrials.gov ID NCT00737568) conducted in compliance
with the Declaration of Helsinki and informed consent regulations at each partic-
ipating site. Written informed consent was obtained from all study participants.
The study design, methods and statistical analyses have been previously pub-
lished in detail [12]. All authors had access to the study data and reviewed and
approved the final manuscript. Patients wereP18 years of age and had confirmed
CHB (defined as a positive serum hepatitis B surface antigen [HBsAg] test for at
least 6 months) with plasma HBV DNA P3 log10 IU/ml. Patients were receiving
LAM and were confirmed to have LAM-R, defined as the presence of rtM204V/
I ± rtL180M, at screening. In addition, patients had alanine aminotransferase
(ALT) <10  upper limit of normal (ULN), haemoglobin P10 g/dl and neutrophils
P1000 mm3. Patients were required to have a creatinine clearance (CLCr)
P50 ml/min (by the Cockcroft-Gault formula). Exclusion criteria included the
following: patients with decompensated liver disease or HCC, or those
co-infected with hepatitis C, hepatitis D, or HIV.
Study treatment
Patients were randomised 1:1, to receive either TDF 300 mg once daily or the
fixed-dose combination of FTC 200 mg and TDF 300 mg once daily. To maintain
blinding, each patient received identical placebo matched to the drug in the other
treatment group. Randomisation was stratified by HBeAg and ALT level (P2 times
ULN range [43 U/L for males and 34 U/L for females] vs. <2 times ULN).
Efficacy analyses
The primary efficacy endpoint was the proportion of patients with plasma HBV
DNA <69 IU/ml (<400 copies/ml) at week 96 [12]; a pre-defined follow-up analy-
sis at week 240 is reported here. Secondary efficacy endpoints at week 240
included the proportion of patients with plasma HBV DNA <29 IU/ml
(<169 copies/ml), the proportion of patients with normal or normalised (6ULN)
ALT, the proportion of patients with HBeAg loss or seroconversion to anti-HBe
(HBeAg-positive patients), and the proportion of patients with HBsAg loss or
seroconversion. The incidence of virological breakthrough (confirmed HBV
DNAP69 IU/ml after achieving <69 IU/ml, or a confirmedP1log10 IU/ml12 Journal of Hepatology 20increase from nadir) and the development of drug-resistant mutations
(conducted annually in subjects with HBV DNAP400 copies/ml) were evaluated
by the last time-point on treatment. Population sequencing of HBV polymerase/
reverse transcriptase (pol/RT), in vitro phenotypic analyses, and viral genotype
were determined as previously described [11].
Safety analyses
Safety analyses up to week 96 have been described previously [12]. Briefly,
adverse events (AEs) and laboratory tests were assessed at regular intervals
(every 1–3 months) and included pre-specified renal safety parameters of
confirmed change from baseline in serum creatinine ofP0.5 mg/dl, decrease in
CLCr <50 ml/min, and serum phosphorus <2 mg/dl. Dual energy X-ray absorp-
tiometry (DEXA) scans of the hip and spine were performed at baseline and then
at 24-week intervals up to week 96 and at 48-week intervals up to week 240 and
percentage change in mean bone mineral density (BMD) at the hip and spine was
calculated.
Statistical analysis
Statistical analyses have been reported previously [12]. In addition, multivariate
analysis was used to identify factors associated with the achievement of normal
ALT at week 240. The primary efficacy and safety analyses were performed on the
full analysis set which included all patients who were randomised and received at
least one dose of study medication. Patients who withdrew post-randomisation
and prior to receipt of any study medication were excluded. The final enrolled
sample size of 280 provides at least a 90% power to detect a difference of 20%
between the treatment groups.
Results
Study patients
A total of 752 patients were screened and 280 were randomised
to receive TDF (n = 141) or FTC/TDF (n = 139) at 62 study sites in17 vol. 66 j 11–18
Table 1. Virological, biochemical, and serological responses at week 240 (full
analysis set, missing equal to failure).
Characteristic TDF 
(n = 141)
FTC/TDF 
(n = 139)
p value*
Virological responses 
HBV DNA <69 IU/ml (<400 copies/ml) 
Overall, n (%) 117 (83.0) 115 (82.7) 0.96 
HBeAg-positive, n/N (%) 56/67 (83.6) 56/66 (84.8) 0.84
HBeAg-negative, n/N (%) 61/74 (82.4) 59/73 (80.8) 0.80
HBV DNA <29 IU/ml  (<169 copies/ml) 
Overall, n (%) 115 (81.6) 114 (82.0) 0.93
HBV DNA, change from baseline in log10 copies/ml
Overall, mean (SD) -4.18 (1.8) -4.26 (2.0) 0.65
HBeAg-positive, mean (SD) -5.02 (1.7) -5.12 (1.6) 0.85
HBeAg-negative, mean (SD) -3.39 (1.6) -3.46 (2.0) 0.92
Biochemical responses 
ALT normalisation 
Overall†, n/N (%) 51/79 (64.6) 59/83 (71.1) 0.41
ALT normal
Overall, n/N (%) 101/141 (71.6) 100/139 (71.9) 0.97
Serological responses
HBeAg loss
Overall, n/N (%) 16/65 (24.6) 13/68 (19.1) 0.41
HBeAg seroconversion
Overall‡, n/N (%) 8/65 (12.3) 7/68 (10.3) 0.67
HBsAg loss
Overall, n/N (%) 2/141 (1.4) 4/139 (2.9) 0.40
HBsAg seroconversion
Overall, n/N (%) 0 1/139 (0.7) 0.32
⁄p values were from a stratified CMH test controlled for randomisation strata and
a two-sided Wilcoxon rank sum test for categorical data and continuous data,
respectively.
yThe denominator is the N of subjects with abnormal ALT at baseline.
The denominator is the N of subjects that are HBeAg positive.
ALT, alanine aminotransferase; CMH, Cochran-Mantel-Haenszel; FTC, emtric-
itabine; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV,
hepatitis B virus; SD, standard deviation; TDF, tenofovir disoproxil fumarate.
JOURNAL OF HEPATOLOGYNorth America, Europe and New Zealand between October 2008
and January 2010 (Fig. 1). The most frequent reasons for screen-
ing failure were HBV DNA levels below the entry threshold, lack
of documented LAM resistance or not receiving LAM concurrent
with time of screening. A total of 239 (85.4%) patients completed
240 weeks of treatment (TDF, 121/141 [85.8%]; FTC/TDF, 118/139
[84.9%]). Reasons for discontinuation were similar between
groups (Fig. 1).
Baseline demographics and disease characteristics were gen-
erally balanced between the two treatment groups as previously
described [12]. Briefly, the majority of the patients enrolled were
male (75%) and Caucasian (61%). Thirty-four percent of patients
were Asian. At baseline, the mean age (standard deviation, SD)
was 46.7 (13.6) years. Almost half (47.5%) of those enrolled were
HBeAg-positive and the predominant HBV genotypes were A
(22%), C (19%), and D (45%). Baseline mean (SD) HBV DNA and
ALT values were 5.70 (1.90) IU/ml, and 79 (122) U/L, respectively,
and mean (SD) CLCr was 93.0 (22.7) ml/min. Baseline mean (SD)
spine and hip BMD were 1.1 (0.19) g/cm2 and 1.0 (0.15) g/cm2,
in the TDF and FTC/TDF groups respectively and 33.8% (91/269)
and 22.1% (59/267), and 7.1% (19/269) and 1.1% (3/267) patientsJournal of Hepatology 20had T scores consistent with either osteopenia (>2.5 to <1) or
osteoporosis (62.5). Mean (SD) CLCr was 93.0 (22.7) ml/min,
respectively. The duration of previous LAM treatment was similar
between groups (mean: 3.8 years).
Efficacy
Virological response
The proportion of patients achieving the study endpoint of
plasma HBV DNA <69 IU/ml (<400 copies/ml) at week 240 was
similar between treatment groups (TDF, 117/141 [83.0%]; FTC/
TDF, 115/139 [82.7%], p = 0.96) (Table 1). Patients receiving either
TDF or FTC/TDF maintained similar treatment responses through
to week 240. At all time-points during the study the proportion of
patients achieving HBV DNA levels <69 IU/ml was similar
between treatment groups (Fig. 2). The proportion of patients
achieving HBV DNA levels of <29 IU/ml (<169 copies/ml) at week
240 was also similar between groups (p = 0.93, Table 1), and also
did not differ at any time-points during the study.
The mean changes in HBV DNA from baseline through to week
240 were similar between treatment groups (p = 0.65, Table 1).
When stratified by HBeAg status there was no significant differ-
ence (p = 0.33 [HBeAg-positive], p = 0.32 [HBeAg-negative])
between treatment groups although the mean HBV DNA decline
was greater in HBeAg-positive patients than in HBeAg-negative
patients (Table 1). However, HBeAg-positive patients had higher
mean (SD) baselineHBVDNA levels thanHBeAg-negative patients;
7.37 (±1.7) log10 copies/ml vs. 5.64 (±1.7) log10copies/ml.
Biochemical response
The percentage of patients with ALT values above the normal
range was similar between treatment groups at baseline [12]
and the percentage of patients who achieved ALT normalisation
at week 240 was similar between groups (p = 0.41) (Table 1).
Factors associated with lack of achievement of normal ALT at
week 240 were high baseline ALT levels (p < 0.01) and high base-
line body mass index (BMI) in the overall population (p = 0.03) as
well as in female patients (p = 0.03). Additional information on all
factors that were analysed are provided in Supplementary
Table 1.
Serological response
By week 240, 29 (21.80%) patients achieved HBeAg loss and 15
(11.3%) patients achieved HBeAg seroconversion with similar
rates between treatment groups (p = 0.41 and p = 0.67, respec-
tively, Table 1). When rates of HBeAg seroconversion were
assessed according to baseline ALT levels, seven patients with
baseline ALTP2  ULN (TDF, 4; FTC/TDF, 3) and eight patients
(TDF, 4; FTC/TDF, 4) with ALT <2  ULN at baseline achieved
HBeAg seroconversion. Overall, six patients (2%) [TDF, 2; FTC/
TDF, 4], achieved HBsAg loss by week 240 of which three patients
[TDF, 1; FTC/TDF, 2] were HBeAg-positive at baseline and three
patients [TDF, 1; FTC/TDF, 2] were HBeAg-negative at baseline.
Only one patient in the FTC/TDF treatment group experienced
HBsAg seroconversion by week 240 (Table 1).
Resistance surveillance
The presence of known drug resistance mutations at baseline has
been previously reported [11]. Eleven patients (TDF, 4/141 [2.8%],
FTC/TDF, 7/139 [5.0%]) were viraemic at week 240 or their last
study visit and qualified for sequence analysis of pol/RT. Of the17 vol. 66 j 11–18 13
TDF
(n = 4)
n = 2
n = 1
Conserved site change
n = 1
n = 1
n = 3 n = 3
No change
Polymorphic site change
Unable to sequence 
due to low viral load
FTC/TDF
(n = 7)
Fig. 3. Sequence results for qualifying TDF and FTC/TDF patients. Patients who
were viraemic at week 240 or their last study visit qualified for sequence analysis
of pol/RT. FTC, emtricitabine; pol/RT, polymerase/reverse transcriptase; TDF,
tenofovir disoproxil fumarate.
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Research Article11 patients that qualified for sequence analysis, one qualified due
to virological breakthrough. Sequence analysis results are shown
in Fig. 3. Over half of these patients (7/11 [64%]) were non-
adherent to study medication at the time of qualification (as
assessed by measuring plasma tenofovir levels). Overall,
sequence analysis demonstrated no sequence changes in four0
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14 Journal of Hepatology 20patients, unique polymorphic-site substitutions in two patients
(including the patient with virological breakthrough), and
conserved-site substitutions in three patients. Sequence analysis
was not possible in two patients due to low viral load. Of the
three patients who had conserved-site substitutions (rtA87G,
rtM/I204I, rtI233V) two were non-adherent to study medication;
none were associated with tenofovir resistance in vitro (fold
change <2). No TDF resistance was observed through 240 weeks
of treatment.
Impact of prior treatment and baseline resistance mutations on
virological response
Given the number of patients with prior ETV exposure, ADV
exposure, and ETV resistance mutations at baseline, an evaluation
was performed to see if they had an impact on long-term treat-
ment response. The decrease in mean HBV DNA levels was sus-
tained up to week 240 regardless of prior treatment exposure
to ETV or ADV or resistance to ETV and the decline between
patients with LAM-R and ETV-R, and LAM-R only was similar
(Fig. 4).
Safety
General safety profile
The overall incidence of treatment-emergent AEs was similar
between treatment groups (Table 2). The most frequent
treatment-emergent AEs were nasopharyngitis (15.7%), headache
(15.5%), fatigue (10.4%) and arthralgia (10.0%). Nine (3%) patients
discontinued due to an AE (TDF, 4; FTC/TDF, 5). Four patients
(two in each treatment group) experienced an on treatment hep-
atic flare. Seven deaths were reported (TDF, 3; FTC/TDF, 4), none
of which were considered related to study treatment (one case of
each of the following: cardiac arrest, pneumonia, bladder cancer,
pancreatic cancer, polytrauma, hepatoma, and gastrointestinal
bleeding).
Renal-related safety profile
Overall two patients, both in the TDF group, had a confirmed
increase in serum creatinine of P0.5 mg/dl (>44 lmol/L) from
baseline. One subject who had a serum creatinine value of
0.9 mg/dl and CLCr of 80 ml/min at baseline, experienced a single
episode of confirmed increase in serum creatinine to 1.4 mg/dl
(CLCr of 55 ml/min) at week 156; the event resolved within
4 weeks after stopping TDF. The other subject with a baseline
serum creatinine value of 1.0 mg/dl and CLCr of 65 ml/min,0
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Table 2. Safety profile up to week 240.
Parameter TDF  
(n = 141)
FTC/TDF
(n = 139)
Total
(N = 280)
Any treatment-emergent AE, n (%) 110 (78.0) 110 (79.1) 220 (78.6)
Grade 3 or 4 AEs, n (%) 16 (11.3) 24 (17.3) 40 (14.3)
Treatment-emergent SAE related 
to study drug* 
0 1 (0.7)** 1 (0.4)
AEs leading to study drug 
discontinuation
4 (2.8) 5 (3.6) 9 (3.2)
Deaths, n (%) 3 (2.1) 4 (2.9) 7 (2.5)
On-treatment hepatic flare, n (%) 2 (1.4) 2 (1.4) 4 (1.4)
Hepatocellular carcinoma 2 (1.4) 1 (0.7) 3 (1.1)
Serum creatinine ≥0.5 mg/dl 
(>44 µmol/L) above baseline, n (%)
2 (1.4) 0 2 (0.7)
CLCr <50 ml/min, n 10 (7.1) 9 (6.5) 19 (6.8)
Serum phosphate <2.0 mg/dl 
(0.65 mmol/L), n (%)
2 (1.4) 1 (0.7) 3 (1.1)
*AE/SAE judged by the investigator to be related to study drug.
**ALT elevation.
AE, adverse event; ALT, alanine aminotransferase; CLCr; creatinine clearance; FTC,
emtricitabine; SAE, serious adverse event; TDF, tenofovir disoproxil fumarate.
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JOURNAL OF HEPATOLOGYexperienced a single episode of confirmed increase in serum
creatinine to 1.6 mg/dl (CLCr 39 ml/min) at week 216; the patient
was subsequently lost to follow-up.
Nineteen patients (6.8%) had confirmed CLCr <50 ml/min
(baseline CLCr values ranged from 49–86 ml/min in these sub-
jects), of which 12 underwent dose modification, three discontin-
ued study treatment, and four received the full dose of study
treatment. Twelve of the 19 patients who had a confirmed
CLCr <50 ml/min had a dose modification to every-other-day dos-
ing, two of these patients discontinued TDF within 6 months after
the start of the dose modification. Of the seven patients who did
not have a dose modification, one patient (FTC/TDF arm) discon-
tinued from the study drug within 6 months after the confirmed
decrease in CLCr. Three patients (TDF, 2; FTC/TDF, 1) had experi-
enced confirmed decreases in serum phosphate values <2.0 mg/
dl (0.65 mmol/L), that were generally transient in nature,
resolved without treatment, and were not associated with
increases in serum creatinine or decreases in CLCr (Table 2).
Bone-related safety profile
Similar declines in BMD were observed for each treatment group
that differed over time at the hip and spine (Fig. 5). At the spine
the decline reached a nadir at week 24 and subsequently sta-
bilised over 240 weeks (Fig. 5A). For both groups combined, mean
percentage change (SD) in BMD at the spine was 0.98% (4.8) at
week 240 with a maximum decline of 1.8% seen at week 24. At
baseline, 59%, 34%, and 7% of patients overall had BMD T scores
in spine consistent with normal bone (P1), osteopenia (1 to
2.5) and osteoporosis (62.5), respectively. At week 240, 53%,
37%, and 10% had T scores in the normal, osteopenic and osteo-
porotic range, respectively.
Declines in hip BMD were progressive over the duration of the
study; at week 240 the mean percentage change (SD) in BMDwas
2.54% (3.5) (Fig. 5B). At baseline, 77%, 22%, and 1% of patients
overall had hip T scores consistent with normal bone, osteopenia
and osteoporosis, respectively. At week 240, 68%, 30%, and 1% of
patients had hip T scores that were consistent with normal bone,
osteopenia and osteoporosis, respectively.Journal of Hepatology 20Overall, the proportion of patients with BMD T scores consis-
tent with osteopenia and osteoporosis increased from baseline to
week 240 by six percentage points for the spine (41%–47%) and
eight percentage points (23%–31%) for the hip.
Ten fractures were reported in seven patients. In the TDF
group, three patients experienced fractures; Grade 2 foot fracture
(1), Grade 3 fractures of the ankle and fibula (1) and simultaneous
Grade 2 fractures of the clavicle, scapula, and skull base (1). In the
FTC/TDF group, four patients experienced fractures; Grade 3
clavicle fracture (1), Grade 1 ankle fracture (1), Grade 2 foot frac-
ture (1), and Grade 2 humerus fracture (1). Information regarding
trauma association was available for six of these patients; this
indicated that all the fractures were trauma associated. None of
the fractures resulted in dose modification, interruption or
discontinuation of study treatment. All fractures were considered
unrelated to study treatment.Discussion
In this prospective, randomised, controlled, long-term trial, TDF
monotherapy provided highly effective viral suppression in
LAM-R patients. Combination therapy with FTC and TDF did not
demonstrate any additional virological benefit. Over 5 years,
one of the longest follow-up periods compared with previous
trials in LAM-R patients, TDF treatment was well tolerated; renal
events observed were generally mild, and decreases in BMD were
seen.17 vol. 66 j 11–18 15
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Our findings are in accordance with those in published litera-
ture that have shown that TDF monotherapy is an appropriate
treatment option for LAM-R patients in terms of virological
response and prevention of developing additional resistance
[13]. The HBV DNA suppression rates observed in this study are
consistent with those reported at week 96 [12] and showed that
TDF monotherapy results in excellent rates of virological sup-
pression in patients with LAM-R. These findings are similar to
those reported in previous studies of TDF monotherapy and
TDF combination therapy in LAM-R patients [13–15]. van
Bömmel and colleagues [14] found that all LAM-R patients trea-
ted with TDF monotherapy achieved viral suppression at week
48, and reported similar results more recently with 95% of
LAM-R patients achieving HBV DNA suppression within a median
of 3.5 months [15]. Importantly, the virological suppression rates
observed in LAM-R patients treated with TDF monotherapy are
higher than those reported in LAM-R patients treated with ETV
or ADV combination therapy [16]. In the current study, 83% of
TDF-treated patients with or without FTC achieved HBV
DNA <69 IU/ml at week 240, whilst only 36% of LAM-R patients
treated with ETV and 51% of those treated with ETV + ADV for a
median duration of 10.4–84.3 months achieved virological sup-
pression [16].
Despite high rates of virological suppression approximately
one-third of patients did not normalise ALT; however, this is con-
sistent with our findings at week 96 and also with ALT normali-
sation rates reported in other trials of FTC/TDF and ETV that
included LAM-R patients [17,18]. The reasons for persistently ele-
vated ALT in virally suppressed patients remain unclear but are
likely multifactorial and could include other causes of liver dis-
ease, such as non-alcoholic fatty liver disease/steatosis [19–21].
In this study, modest rates of HBeAg loss and HBeAg serocon-
version were observed. Although our findings are lower than
those reported in treatment-naïve patients [22,23] they are con-
sistent with studies of TDF and FTC/TDF in treatment-
experienced CHB patients. Berg and colleagues reported rates of
HBeAg loss in the range of 22%–24% in ADV-experienced patients
[17], and Kuo and colleagues also reported HBeAg loss of 11% of
LAM-R patients [24]. Rates of HBeAg seroconversion in our study
were 12.3% in the TDF group and 10.3% in the FTC/TDF group,
which are similar to those rates reported in LAM-refractory
patients treated with ETV and in patients treated with LAM,
TDF or ADV [25,26]. Furthermore, a higher proportion of patients
with baseline ALTP 2  ULN achieved HBeAg seroconversion
compared with patients with lower baseline ALT, providing evi-
dence to suggest that seroconversion is higher in patients with
elevated ALT at baseline.
The low rates of HBsAg loss observed in this study are consis-
tent with other studies evaluating the long-term treatment with
oral antiviral agents in LAM-R patients [14,26,27]. In mostly
treatment-naïve HBeAg-positive patients treated with TDF for
up to 8 years, 11.8% of patients experienced HBsAg loss. Analysis
of factors associated with HBsAg loss showed that Caucasian
race, a shorter duration of HBV infection (64 years), baseline
HBsAg level (not assessed in this trial), and presence of HBV
genotypes A or D were associated with greater likelihood of
HBsAg loss at 240 weeks [28]. We also observed low rates of
HBsAg seroconversion (<1% overall) which are lower than those
reported by Berg and colleagues in ADV-experienced patients
treated with TDF or FTC/TDF followed for the shorter duration
of 168 weeks [17].16 Journal of Hepatology 20An important finding from this study is that no patient devel-
oped TDF resistance after 240 weeks of continuous treatment,
even in patients harbouring baseline resistance mutations. The
lack of resistance to TDF through 5 years of continuous treatment
is striking considering the high rates observed in studies of other
antiviral agents used for a similar duration. Tenney and
colleagues reported a cumulative probability of genotypic ETV
resistance of about 50% in LAM-refractory patients who were
switched to ETV monotherapy [9]. Whilst Ze et al. reported rates
of resistance development in 14% of LAM-R patients retreated
with LAM + ADV and of 72% in ETV-treated patients [29]. These
studies highlight the need for treatment options which do not
confer a risk of resistance development in LAM-R patients, partic-
ularly in regions such as Asia, where LAM is commonly used [30].
The absence of viral resistance observed in this study has impor-
tant clinical implications because patients who do not develop
resistance may have a lower risk of disease progression [17,31].
Overall, 240 weeks of TDF as monotherapy or in combination
therapy was well tolerated and there were few discontinuations
due to AEs, which is consistent with the findings of other studies
of TDF treatment in both treatment-naïve and treatment-
experienced patients [17,32,33]. Given that TDF is renally
metabolised there is a potential for kidney-specific toxicity and
TDF-associated increased risk of tubulopathy [34]. Importantly,
only 8.57% of patients overall experienced abnormalities in renal
laboratory parameters and patients who experienced confirmed
reductions in CLCr <50 ml/min were managed by dose modifica-
tion. Phosphate levels in all patients who experienced decreases
during treatment had normalised at week 240 without dose mod-
ification, which suggests that the effects of TDF on renal function
are not a substantial concern, although regular monitoring is
required.
This is the first study to prospectively evaluate changes in
BMD from baseline using serial DEXA scans in an adult CHB pop-
ulation for 240 weeks. Interestingly, the percentage change in
spine BMD reached a nadir at week 24 and subsequently sta-
bilised over 240 weeks whilst the percentage change in hip
BMD progressively decreased up to week 240. Although direct
comparison with other studies is not possible, the declines in
BMD we report are consistent with those reported at the hip in
studies evaluating TDF/LAM and efavirenz in HIV-infected sub-
jects. Although there was an increase from baseline to week
240 in the proportion of patients with BMD T scores at the spine
and hip consistent with osteopenia and osteoporosis, there was a
low occurrence of fractures observed in the study overall and
therefore the clinical significance of this, if any, is unknown. It
would be useful to determine the role of nutrition and other
factors in the BMD analyses. However, vitamin D and calcium
supplementation was not a protocol requirement of our study
and vitamin D levels were not assessed. Therefore, additional
studies are required to determine the effect of these factors on
any TDF-related effects on BMD.
In this study the degree of fibrosis and/or the presence of
cirrhosis in patients was assessed at screening using the patient’s
medical history. However liver biopsies were not taken and non-
invasive markers of fibrosis (FibroTest and FibroScan) were not
assessed so we are unable to draw any conclusions about the
impact of long-term treatment on fibrosis stage. Our study is also
limited by the small proportion of patients who had previously
been treated with ADV monotherapy and these patients were
not evenly distributed between treatment groups. As only 2% of17 vol. 66 j 11–18
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patients had ADV resistance (rtA181T/C/G/S/V) at baseline and no
patients harboured rtN236T, it is not possible to infer any effect
of TDF in patients with ADV resistance. Similarly, as the number
of patients with a complex resistance profile was small, the
results from this study cannot be applied to patients with multi-
ple nucleoside-nucleotide resistance.
In conclusion, our long-term results demonstrate that TDF
alone for the treatment of CHB is effective and well tolerated in
LAM-R patients. There was no evidence of an additional treat-
ment benefit from combination therapy with FTC/TDF. Impor-
tantly, 240 weeks of continuous therapy with TDF alone, or in
combination with FTC, was not associated with resistance devel-
opment. TDF is, therefore, an effective and well tolerated treat-
ment option for CHB patients with resistance to lamivudine.Financial support
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